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ABSTRACT
The PI3K pathway is frequently hyperactivated in primary T-cell acute lymphoblastic 
leukemia (T-ALL) cells. Activation of the PI3K pathway has been suggested as one 
mechanism of glucocorticoid resistance in T-ALL, and patients harboring mutations 
in the PI3K negative regulator PTEN may be at increased risk of induction failure and 
relapse. By gene expression microarray analysis of T-ALL cells treated with the PI3K 
inhibitor AS605240, we identified Myc as a prominent downstream target of the PI3K 
pathway. A significant association was found between the AS605240 gene expression 
signature and that of glucocorticoid resistance and relapse in T-ALL. AS605240 showed 
anti-leukemic activity and strong synergism with glucocorticoids both in vitro and in a 
NOD/SCID xenograft model of T-ALL. In contrast, PI3K inhibition showed antagonism 
with methotrexate and daunorubicin, drugs that preferentially target dividing cells. 
This antagonistic interaction, however, could be circumvented by the use of correct 
drug scheduling schemes. Our data indicate the potential benefits and difficulties for 
the incorporation of PI3K inhibitors in T-ALL therapy.
INTRODUCTION
T-cell acute lymphoblastic leukemia (T-ALL) is 
an aggressive hematologic cancer [1]. The prognosis 
of children with T-ALL has improved with modern 
treatment protocols, based on the use of aggressive multi-
agent therapies [2]. However, T-ALL patients displaying 
chemotherapy resistance show very poor survival. 
Accumulating evidence indicates that the PI3K pathway is 
linked to resistance to therapy in several types of cancer [3].
Class I PI3Ks are a family of lipid kinases 
predominantly activated by protein tyrosine kinases in 
response to cell surface receptors. PI3K phosphorylates 
phosphatidylinositol 4, 5-bisphosphate (PIP2) generating 
phosphatidylinositol 3, 4, 5-trisphosphate (PIP3). PIP3 
serves as an anchor for pleckstrin homology (PH) 
domain-containing proteins, which initiate the assembly 
of signaling complexes that results in the activation of a 
plethora of downstream effector molecules, including 
protein kinase B (Akt) [4] and the mammalian target of 
rapamycin complex 1 (mTORC1) [5]. The PI3K pathway 
is central to the control of cell survival, energy metabolism, 
cellular motility and cell cycle progression [6–7].
Constitutive activation of the PI3K pathway in 
hematological malignancies has been shown to support 
tumor cell proliferation, viability and drug resistance in vitro 
[8–10]. Moreover, PI3K signaling pathway is frequently 
hyperactivated in primary T-ALL cells, for instance due 
to microenvironmental stimulation, interleukin-7 receptor 
(IL7R) oncogenic mutations or phosphatase and tensin 
homolog (PTEN) inactivation [11–15]. Activation of the 
PI3K effector mTOR in T-ALL has been suggested to 
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represent one mechanism of resistance to glucocorticoids, a 
common feature of relapse [16–17]. Moreover, synergistic 
effects of inhibitors of the PI3K-downstream mTOR 
pathway in T-ALL cell lines have been described [18–19]. 
We and others have shown that T-ALL patients harboring 
PTEN mutations may be at increased risk of induction 
failure and relapse [13, 20]. Importantly, PTEN aberrations 
were associated with poor outcome and relapse in T-ALL 
[20–22], suggesting that the level of PI3K activation may 
influence resistance to treatment.
In this study, T-ALL cells were treated with a PI3K 
inhibitor to identify a transcriptional PI3K activity signature. 
PI3K inhibition downregulated genes associated with cellular 
growth and targets of Myc. Moreover, the comparison of the 
PI3K signature with gene expression data of primary T-ALL 
samples indicates that higher PI3K activity is associated 
with glucocorticoid resistance and worse clinical outcome. 
We opted to use the PI3K inhibitor AS605240 in light of its 
favorable pharmacological and biochemical characteristics 
[23–24]. This allowed us to test the long term inhibition 
effects of PI3K in a NOD/SCID xenograft model of T-ALL. 
Functional assays demonstrated that PI3K inhibition 
sensitizes T-ALL cells to glucocorticoids, but antagonizes 
methotrexate (MTX) and daunorubicin (DNR), unless correct 
drug scheduling is used.
RESULTS
PI3K activity is associated with increased 
chemotherapy resistance and poor prognosis in 
T-ALL
Most cell lines are maintained in culture for years 
and accumulate several genetic lesions not characteristic 
of primary disease [25]. On the other hand, ALL primary 
cells do not divide in vitro [26], which may affect their 
response to small molecules [27]. Hence, we decided to 
obtain transcriptional signatures of PI3K activity from 
both cell lines and primary cells, which would provide 
complementary aspects of gene expression modulation 
by PI3K. To do so, seven T-ALL cell lines [GSE50998] 
and 15 diagnostic T-ALL patient samples [GSE51000] 
were treated with the PI3K inhibitor AS605240 or 
vehicle for 6 h, and subjected to global gene expression 
analysis using whole-transcript Affymetrix expression 
arrays. Principal Component Analysis (PCA) showed 
that most samples responded similarly to PI3K inhibition, 
irrespectively of PTEN and NOTCH1 mutational status 
(Supplementary Figure 1). Using paired Limma analysis, 
we obtained 211 genes downregulated and 78 genes 
upregulated in T-ALL primary cells (adjusted p-value < 
0.05, FC > 1.5; Supplementary Table 1) and 174 genes 
downregulated and 395 genes upregulated in T-ALL cell 
lines (adjusted p-value < 0.05, FC > 1.5; Supplementary 
Table 2) in response to AS605240 treatment. As expected, 
Connectivity Map analysis showed that the signature 
resulting from PI3K inhibition in T-ALL cell lines 
correlated with signatures of classical PI3K inhibitors 
(wortmannin and LY-294002), and rapamycin (sirolimus; 
Supplementary Figure 2). Rapamycin is an inhibitor of 
mTORC1, a complex downstream of PI3K signaling [5]. 
Although other interpretations may be possible, genes 
downregulated by AS605240 were here considered to be 
under positive transcriptional control of PI3K, whereas 
those upregulated by AS605240 were considered under 
negative control of PI3K.
GSEA analysis showed that AS605240 treatment 
downregulated several gene sets related to cellular 
growth in both T-ALL cell lines and primary cells, 
including energy metabolism (glucose transport and 
metabolism, oxidative phosphorylation, pyruvate 
metabolism, and TCA cycle), transcription (nucleotide 
metabolism, RNA polymerase III transcription, tRNA 
and miRNA biosynthesis) and biosynthesis of a plethora 
of compounds and cellular structures (biosynthesis 
of purines, pyrimidines, amino acids, glucose, fatty 
acids and steroids, and biogenesis of lysosome vesicles 
and mitochondria). Among the top tier of gene sets 
transcriptionally downregulated by AS605240 in both cell 
lines and primary cells, four different gene sets represented 
targets of Myc (Figure 1a–1d; Supplementary Figure 3a-b) 
[28–30]. A fifth gene set representing a Myc oncogenic 
signature [31] was downregulated by AS605240 in cell 
lines (Supplementary Figure 3b).
The transcription factor Myc is a master regulator 
of cell growth and multiple biosynthetic and metabolic 
pathways [32], and its expression correlates with leukemia 
initiating activity in T-ALL [33]. Myc inhibition by 
AS605240 appeared to be Notch1-independent, since 
Notch1 direct targets [34] were not transcriptionally 
modulated (Figure 1e–1f). On the other hand, a broader 
gene set of Notch1-responsive genes, which includes several 
Myc targets [35], was significantly downregulated in cell 
lines treated with AS605240 (Supplementary Figure 3c). 
Although MYC mRNA levels were not significantly altered 
after 6 h of AS605240 treatment (data not shown), western 
blotting analysis evidenced decreased Myc protein levels in 
Jurkat and Molt-4 cells after PI3K inhibition (Figure 1g). 
Quantitative PCR confirmed downregulation of Myc 
targets ALOX5AP, BCAT1, PRDX4 and LDHA in primary 
cells treated with AS605240 (Supplementary Figure 3d). 
BCAT1 was found to induce cell proliferation, migration 
and invasion in nasopharyngeal carcinoma [36]. LDHA 
and PRDX4 were described as overexpressed in high-risk 
neuroblastomas independently of other markers [37–38].
Ingenuity Pathway Analysis showed that the 
top biological functions downregulated by AS605240 
in both cell lines and primary cells were related to 
cholesterol biosynthesis (Supplementary Figure 4). 
Glucocorticoid resistance in T-ALL has been associated 
to the upregulation of genes linked to cellular respiration, 
biosynthetic and metabolic pathways, proliferation 
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and Myc. Notably, genes responsible for cholesterol 
biosynthesis were found highly upregulated in 
prednisolone resistant T-ALL [39], and ALL cells were 
shown to be particularly dependent on endogenously 
synthesized cholesterol, which is essential for the synthesis 
of cellular membranes of highly proliferative cells [40]. 
Because PI3K inhibition targeted genes involved in Myc 
signaling, cellular growth, and cholesterol biosynthesis, 
we hypothesized that the AS605240-derived signature 
would be correlated with gene expression patterns of 
glucocorticoid resistance in T-ALL. Indeed, GSEA 
analysis showed that genes associated with prednisolone 
resistance [39] were downregulated due to PI3K inhibition 
(Figure 1h), whereas those associated with prednisolone 
sensitivity [39] were upregulated (Figure 1i).
The PI3K activity signatures were then compared 
against expression microarray data of 43 primary T-ALL 
samples obtained at diagnosis from patients treated under 
Figure 1: PI3K inhibition downregulates Myc in a Notch1-independent manner and is associated to glucocorticoid 
sensitivity. GSEA heatmaps (a-b) and enrichment plots (c-d). Targets of Myc [28–30] are downregulated in T-ALL cell lines (CCRF-CEM, 
HPB-ALL, Jurkat, Molt-4, P12-ICHIKAWA, ALL-SIL and TALL-1, from left to right in heatmaps) and primary cells upon treatment with 
the PI3K inhibitor AS605240 for 6 h. We show representative plots corresponding to the gene set described in Schuhmacher et al., 2001 
(SCHUHMACHER_MYC_TARGETS_UP) [30]. Additional plots are provided in Supplementary Figure 3. In heatmaps, red and blue tones 
indicate higher or lower expression, respectively. Leading edge genes are indicated. (e-f) GSEA enrichment plots. Direct targets of Notch1 
[34] were not significantly modulated by AS605240. (g) AS605240 inhibits accumulation of Myc protein. Western blotting of Myc and β-actin 
of Jurkat and Molt-4 cells treated with the IC50 values of AS605240 or vehicle for 6 h and 12 h. (h-i) Genes discriminative for prednisolone 
resistance [39] were downregulated in AS605240-treated cell lines and genes discriminative for prednisolone sensitivity [39] were upregulated 
in AS605240-treated ones.
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the GBTLI ALL-99 [41] and GBTLI-2009 protocols at 
Centro Infantil Boldrini [GSE50999] (for clinical and 
biological data, refer to Supplementary Table 3). GSEA 
analysis showed that patients that underwent relapse had 
higher expression of genes under positive control of PI3K 
(downregulated by AS605240) and lower expression 
values of genes under negative control of the pathway 
(upregulated by AS605240; Figure 2). Altogether, our gene 
expression data suggest that higher PI3K activity may be 
associated with increased glucocorticoids resistance and 
poor prognosis, which is in accordance with previous data 
showing that PTEN mutated patients may be at increased 
risk of early treatment failure and relapse [13, 20].
The PI3K inhibitor AS605240 shows anti-leukemic 
activity and prevents leukemic progression in 
T-ALL engrafted NOD/SCID mice
Next, we sought to characterize the effects of 
AS605240 against T-ALL cells, with the goal of pre-
clinically assessing the potential benefits of PI3K inhibition 
in T-ALL. AS605240 inhibited p-Akt (Figure 3a–3b) and 
PIP3 (Figure 3c) accumulation and promoted apoptosis in 
both T-ALL cell lines and primary cells, with activation 
of Caspase-3 (Figure 3d, Supplementary Figure 5). The 
IC50 concentrations of AS605240 in a 96 h assay ranged 
from 12 to 22 μM depending on the cell line tested (Figure 
3b, Supplementary Figure 6). These values are within 
the same range necessary to inhibit approximately 75% 
of PIP3 accumulation in Jurkat cells (Figure 3b). The 
lower survival plateau reached zero in all cell lines and 
no correlation was found between IC50 concentrations 
and PTEN mutational status (data not shown). Notably, 
T-ALL primary cells were significantly more sensitive to 
AS605240 than normal human thymocytes (Figure 3e).
To test the in vivo efficacy of AS605240 treatment, 
NOD/SCID mice were transplanted with primary T-ALL 
cells derived from one patient sample and randomized 
eleven days later to receive AS605240 (20mg/kg) or 
vehicle, intraperitoneally twice a day, 5 days a week. 
Mice treated with the PI3K inhibitor showed decreased 
leukemic progression in comparison to control mice, as 
evaluated by the percentage of human CD45+ cells in 
peripheral blood at different time points (Figure 3f).
AS605240 synergizes with glucocorticoids both 
in vitro and in a mouse xenograft model of 
T-ALL
To further evaluate the clinical potential of PI3K 
inhibition for T-ALL treatment, we measured the cytotoxic 
effect of AS605240 in combination with commonly 
used chemotherapeutic drugs (Table 1). We observed 
a synergistic interaction between AS605240 and a 
glucocorticoid (prednisolone) in 5 out of 6 cell lines tested 
(Figure 4a). Notably, cell lines intrinsically more resistant 
to prednisolone (CCRF-CEM, HPB-ALL and Molt-
4) showed weaker synergism between AS605240 and 
prednisolone, characterized by higher Combination Index 
(CI) values (Figure 4a–4b). According to the COSMIC 
database, cell lines CCRF-CEM, Jurkat and Molt-4 show 
glucocorticoid receptor (NR3C1) missense mutations. 
P12-ICHIKAWA and TALL-1 don’t show alterations in 
NR3C1. The mutations identified in CCRF-CEM and 
Jurkat have been associated with functionally defective 
glucocorticoid receptors [42–43]. In agreement with that, 
these cell lines were more resistant to prednisolone than 
the remaining cell lines analyzed. Jurkat cells showed 
the highest calculated IC50 value of prednisolone. For 
this cell line, we were unable to measure the CI between 
prednisolone and AS605240.
Accordingly, NOD/SCID mice engrafted 
with primary T-ALL cells derived from two patient 
samples showed enhanced survival when treated with a 
Figure 2: Genes responsive to PI3K inhibition show differential expression in T-ALL samples of patients who 
underwent relapse. Diagnostic T-ALL samples of patients who underwent relapse showed (a) higher expression of genes downregulated 
by AS605240 and, conversely, (b) lower expression of genes upregulated by AS605240 in primary cells in vitro.
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combination of AS605240 (30 mg/kg once a day) and 
another glucocorticoid (dexamethasone), in comparison to 
treatment with either drug alone (Figure 4c). Noteworthy, 
no difference was observed in weight loss of T-ALL 
transplanted NOD/SCID mice treated with AS605240 
versus dexamethasone (Supplementary Figure 7). In 
conclusion, our data strongly suggest that PI3K inhibition 
potentiates the activity of glucocorticoids against T-ALL 
cells both in vitro and in vivo.
PI3K inhibition requires scheduling when 
combined with drugs that target dividing cells
AS605240 showed an antagonistic interaction 
in vitro with both MTX (Table 1; Figure 5a) and 
DNR (Table 1) in all cell lines tested. MTX is an 
antimetabolite that allosterically inhibits dihydrofolate 
reductase (DHFR), which participates in the synthesis of 
tetrahydrofolate, an essential molecule for the biosynthesis 
of purines, thymidylate and several amino acids [44]. 
MTX acts specifically during DNA and RNA synthesis, 
and thus it is cytotoxic during the S-phase of the cell cycle. 
AS605240 treatment completely abrogated MTX-induced 
S-phase arrest in vitro (Figure 5b). Part of this antagonistic 
interaction may result from AS605240-induced G0/
G1 cell cycle arrest, which decreases the number of 
S-phase MTX-susceptible cells (Table 2, Figure 5b). 
BrdU incorporation assays also showed decreased rate 
of nucleotide incorporation during S-phase in Jurkat, 
Molt-4 and P12-ICHIKAWA cells after 24 h treatment 
with AS605240 (Table 2, Figure 5c). The lower rate of 
DNA duplication in AS605240-treated cells may induce 
increased tolerance to lower nucleotide availability under 
MTX treatment [45]. Altogether, these results indicate 
that both AS605240-induced cell cycle arrest at G0/G1 and 
the lower rate of DNA replication may contribute to the 
antagonistic interaction between AS605240 and MTX.
Based on these evidences, we explored alternative 
administration schedules to find possible therapeutic 
windows for AS605240 use in the context of modern 
ALL treatment protocols, which include MTX and other 
anticancer drugs that target dividing cells. When AS605240 
Figure 3: AS605240 inhibited p-Akt and PIP3 accumulation in T-ALL and showed anti-leukemic activity both in vitro 
and in vivo. (a) Western blotting analysis for Akt and p-Akt (Ser473) in Jurkat and Molt-4 cells treated with AS605240 IC50 values or 
vehicle. (b) Effect in cell survival and p-Akt accumulation of increasing concentrations of AS605240 in Jurkat cells. Survival was assessed 
by the MTT assay after 96 h of incubation. Quantification of p-Akt was performed with the AKT [pS473] ELISA Kit (Invitrogen) after 
24 h of incubation. (c) AS605240 inhibits PIP3 accumulation, as assessed by PIP3 mass ELISA quantification in Jurkat cells incubated 
for 24 h with AS605240 or vehicle. P-value obtained with a paired T-test. (d) AS605240 induces apoptosis, as assessed by Annexin V/
PI double staining and flow cytometry analysis in Jurkat and primary T-ALL cells treated with AS605240 or vehicle for 8 h and 6 h, 
respectively. Additional plots in Supplementary Figure 5. (e) Primary T-ALL cells (n = 7) are more sensitive to AS605240 than normal 
human thymocytes (n = 7). Cells were incubated with 10 μM of AS605240 for 48 h and survival was assessed by the MTT assay. P-value 
obtained with an unpaired T-test. (f) AS605240 prevents leukemic progression in NOD/SCID mice engrafted with primary T-ALL cells. 
Eleven days after the injection of 107 T-ALL cells, mice started to be treated with 20 mg/Kg of AS605240, intraperitoneally twice a day, 
5 days a week. Peripheral blood proportion of human CD45+ cells was measured by flow cytometry analysis after red blood cells lysis. 
Exponential growth curves were compared with the F test of the best-fit K values. Error bars indicate the standard error of the mean (SEM).
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Figure 4: AS605240 shows a synergistic interaction with prednisolone. (a) MTT assay of T-ALL cell lines treated for 96 h 
with several ratios of the IC50 values of AS605240, prednisolone or both. Combination Index (CI) values are indicated. Synergistic effect 
is characterized by CI < 0.9 and additive effect by 0.9 > CI > 1.1. (b) MTT assay of T-ALL cell lines treated for 96 h with increasing 
concentrations of prednisolone. (c) NOD/SCID mice engrafted with primary T-ALL cells were treated with 30 mg/Kg of AS605240 and/or 
5 mg/Kg of dexamethasone, intraperitoneally once a day, 5 days a week. Treatment started when human CD45+ accounted for more than 
0.5% of peripheral blood cells after red blood cells lysis.
Table 1: Combination Index (CI) between AS605240 and methotrexate (MTX), prednisolone (Pred), 
asparaginase (Asp) or daunorubicin (DNR) in T-ALL cell lines. MTT assay of cell lines treated for 96h 
with several ratios of the IC50 values of each drug. Combination index (CI) was calculated with the Calcusyn 
software. Synergistic effect is characterized by CI<0.9, additive effect by 0.9<CI<1.1 and antagonistic effect 
by CI>1.1. The columns named Pred, Asp, MTX and DNR represent results obtained with the simultaneous 
use of AS605240 and the respective drug. Columns MTX sched and DNR sched represent the scheduling 
scheme where AS605240 was added to culture media 48h after the respective drug.
Combination index (CI)
Cell line Pred Asp MTX MTX sched DNR DNR sched
CCRF-CEM 0.88 0.84 2.91 1.11 1.76 1.67
HPB-ALL 0.86 1.48 1.23 1.00 1.07 -
Jurkat - 1.07 - 1.62 2.10 -
Molt-4 0.96 1.07 2.55 1.21 1.48 -
P12-ICHIKAWA 0.08 0.93 1.78 0.75 1.27 0.89
ALL-SIL 0.33 1.35 1.39 0.96 1.12 -
TALL-1 0.55 0.94 1.57 1.10 1.63 0.89
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Figure 5: AS605240 showed an antagonistic interaction with MTX, which could be successfully circumvented by means 
of proper drug scheduling. (a) AS605240 shows an antagonistic interaction with MTX when drugs are administered concomitantly. 
MTT assay of T-ALL cell lines treated for 96 h with several ratios of the IC50 values of AS605240, MTX or both. Combination index (CI) 
values are indicated. Synergistic interaction, CI < 0.9; additive interaction, 0.9 < CI < 1.1; antagonistic interaction, CI > 1.1. (b) AS605240 
reduces the percentage of cells in S and completely abrogates MTX-induced S-phase arrest. Molt-4 cells were incubated with the IC50 values 
of AS605240 and/or MTX for 24 h, propidium iodide stained and analyzed by flow cytometry. (c) AS605240 reduces BrdU nucleotide 
incorporation, as shown by reduced anti-BrdU fluorescence intensity of S-phase cells (pink) in Jurkat, P12-ICHIKAWA and Molt-4 cells. 
Cell lines were treated with AS605240 IC50 value for 24 h. Representative plots of P12-ICHIKAWA cells are shown. (d) AS605240 shows 
an additive/synergistic interaction with MTX when the PI3K inhibitor is added 48 h after those drugs (4 out of 7 cell lines tested) in a  
96 h MTT assay. (e) MTT assay of T-ALL cell lines treated for 48 h with increasing concentration of MTX. IC50 values were calculated 
with the GraphPad Prism 5 software.
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was added 48 h after MTX and DNR, we observed lower 
Combination Index values for all cell lines tested. For MTX, 
a synergistic interaction was present in P12-ICHIKAWA 
cells and additive interactions were present in 3 out of 7 cell 
lines tested. For DNR, combination indexes characterizing 
slight synergism were present in 2 out of 3 cell lines (Table 
1, Figure 5d). Noteworthy, when using this schedule, the 
most synergistic interactions were observed for the cell lines 
(HPB-ALL, CI = 1.0; P12-ICHIKAWA, CI = 0.76; ALL-
SIL, CI = 0.96) found to be resistant to MTX in a 48 h 
assay (Figure 5e). Overall, our data indicate that scheduling 
is of major importance when considering the introduction 
of PI3K inhibitors in T-ALL treatment schemes with 
chemotherapeutic drugs that require cell division.
DISCUSSION
Aberrant activation of PI3K signaling pathways 
has been implicated in many types of cancer [46]. 
PTEN mutations and elevated Akt activity were found 
to be associated with poor prognosis in solid tumors 
[47–48] and T-ALL [13, 20]. In this study, we show data 
indicative of higher PI3K pathway activity in patients who 
underwent relapse.
Given that PI3Kγ is predominantly expressed in the 
hematopoietic system [49], the use of a PI3Kγ specific 
inhibitor could offer an innovative rationale-based 
therapeutic strategy for T-ALL. AS605240 was previously 
described as an isoform-selective ATP-competitive 
inhibitor of PI3Kγ with 30-fold selectivity over PI3K δ 
and β, and 7.5-fold selectivity over PI3Kα [23]. However, 
we found that AS605240 did not have cytotoxic effects 
against T-ALL cells at concentrations expected to inhibit 
solely PI3Kγ (0.1–0.2 μM) [23], being cytotoxic only at 
concentrations high enough to inhibit more than 70% of 
p-Akt accumulation (Figure 3b), presumably disrupting 
the activity of several PI3K isoforms. All PI3K p110 
subunits are highly expressed in primary T-ALL cells 
(Supplementary Figure 8) [50] and evidence points to 
roles of PI3Kα, γ and δ in T-ALL leukemogenesis [13, 50], 
suggesting that multiple isoforms of PI3K might play a role 
in T-ALL.
Although the concentrations of AS605240 needed 
to inhibit the PI3K pathway and induce cell death 
in vitro were in the micromolar range, the drug was more 
selective to leukemic cells than to normal thymocytes. 
More importantly, the PI3K inhibitor prevented primary 
T-ALL progression in vivo and may be given to mice for 
months without inducing generalized toxicity [23–24]. 
Although this indicates the feasibility of AS605240 use to 
treat T-ALL patients, we observed that mice had mobility 
difficulties and remained immobile for several minutes 
after AS605240 administration (Supplementary Video). 
This raises the possibility of undesirable neurological side 
effects not previously reported.
This is the first time that gene products downstream 
of PI3K have been identified in T-ALL. Interestingly, 
we observed a prominent effect of PI3K inhibition on 
the expression of Myc target genes. The PI3K/Akt/
mTORC1 pathway is known to positively regulate Myc 
protein abundance. Previous work in T-ALL demonstrated 
that Akt phosphorylates and deactivates Gsk3-beta, 
preventing phosphorylation of Myc and its degradation 
through the ubiquitin/proteasome pathway [51]. mTORC1 
phosphorylates S6K1 which in turn enhances translation 
of Myc mRNA by modulating the phosphorylation 
of eukaryotic initiation factor eIF4B [52]. At the 
transcriptional level, in T-ALL, Myc is under control of 
Notch1 [53]. Our microarray data showed no regulation 
of Notch1 direct targets in response to AS605240, 
suggesting that the effect of this drug on Myc targets most 
likely occurred by posttranscriptional inhibition of Myc. 
Accordingly, Myc protein levels were downregulated in 
response to AS605240.
Glucocorticoids play a role of great importance in 
contemporary ALL treatment protocols. Early response 
to glucocorticoids is an informative prognostic factor 
in childhood ALL [54] and glucocorticoid resistance 
Table 2: AS605240 induces G0/G1 cell cycle arrest and reduces BrdU nucleotide incorporation in 
T-ALL cell lines. Each cell line was treated with the IC50 value of AS605240 for 24h and incubated 
with BrdU for 30 min. Percentage of cells in each phase of the cell cycle and BrdU incorporation were 
measured with the BD BrdU Flow Citometry Assay Kit and flow cytometry analysis
Cell line Treatment G0/G1 (%) S (%) G2/M (%) BrdU in S (Geo 
Mean)
Jurkat Control 48.1 37.8 7.4 2.736
AS605240 55.6 3.3 20.7 1.732
Molt-4 Control 47.0 45.1 4.1 4.751
AS605240 63.8 27.1 4.2 3.587
P12-ICHIKAWA Control 45.8 37.5 6.6 4.357
AS605240 48.3 26.2 9.6 2.623
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is a well-documented feature of relapse [17, 55]. 
Glucocorticoid resistance was previously associated 
with a proliferative phenotype involving upregulation 
of glycolysis, cholesterol biosynthesis, and activation 
of PI3K/Akt/mTOR and Myc signaling pathways [39, 
56]. Indeed, fast growing T-ALL cell lines are more 
resistant to both prednisolone and dexamethasone [39]. 
Previous studies observed a synergistic interaction 
between rapamycin and dexamethasone in T-ALL [16, 
57]. Moreover, the PI3K inhibitor LY294002 sensitized 
MLL-rearranged ALL cells to prednisolone in vitro [58]. 
In the present study, we showed that PI3K inhibition 
promotes downregulation of metabolic and biosynthesis 
pathways towards a gene expression profile more typical 
of glucocorticoid sensitive ALL cases. The PI3K inhibitor 
AS605240 synergized with glucocorticoids in vitro and the 
combined use of AS605240 and dexamethasone enhanced 
survival of mice engrafted with T-ALL. We observed 
no difference between PTEN mutated and wild-type 
transplanted leukemias with respect to AS605240 effect, 
which raises the question if T-ALL patients may benefit 
from PI3K inhibition irrespectively of PTEN mutational 
status. Notably, we observed that T-ALL cell lines 
intrinsically more resistant to prednisolone (CCRF-CEM, 
HPB-ALL and Molt-4) showed weaker synergism between 
AS605240 and prednisolone (Figure 4a–4b). This suggests 
that the PI3K pathway is not the only pathway underlying 
glucocorticoid resistance, corroborating previous findings 
[59]. Recent clinical and preclinical studies have shown 
that RAS mutations limit the effectiveness of PI3K 
inhibitors [60–61].
AS605240 showed an antagonistic interaction with 
MTX and DNR when both drugs were administered 
simultaneously to cell cultures. MTX kills growing 
tumor cells by limiting their supply of dTTP and purine 
nucleotides, which leads to DNA repair defects, DNA 
strand breaks and apoptosis. MTX-induced DNA strand 
break accumulation is minimal in growth-arrested tumor 
cells [45]. The anthracycline DNR increases the levels 
of topoisomerase II:DNA covalently bound complexes, 
generating DNA double strand breaks and inducing 
apoptosis. Anthracyclines appear to be particularly toxic 
during S-phase, when replication forks and transcription 
complexes are both present [62]. Our results showed that 
PI3K inhibition in leukemia cell lines not only induces cell 
cycle arrest at G0/G1, but also decreases DNA synthesis 
rate during cell division. This cytostatic effect is probably 
responsible for the tolerance exhibited by AS605240-
treated cells to MTX and DNR. Our data also showed that 
the antagonistic interaction with MTX and DNR could 
be successfully circumvented by means of proper drug 
scheduling in more than half of the cell lines studied in 
vitro (Figure 5).
Recent evidence shows that genes most significantly 
correlated with ALL resistance to prednisolone are 
inversely correlated with MTX resistance, and that the 
transcriptional networks underlying resistance to one 
drug may actually sensitize cells to the other. Translation 
was suggested as one critical pathway determining the 
balance between glucocorticoid and MTX sensitivity in 
T-ALL [63]. We now provide evidence that this disparate 
prednisolone/MTX transcriptional profile may be under 
PI3K pathway control.
In summary, our gene expression analysis indicated 
that PI3K activity is associated with chemotherapy 
resistance in T-ALL. Accordingly, PI3K inhibition 
sensitized T-ALL cells to glucocorticoids both in vitro 
and in vivo. Furthermore, our data indicate that correct 
scheduling will be of upmost importance when combining 
PI3K inhibitors with drugs targeting dividing cells, which 
are mainstream in current protocols against T-ALL.
METHODS
Ethics Statement. Investigation has been conducted 
in accordance with the ethical standards and according 
to the Declaration of Helsinki and according to national 
and international guidelines. The use of patient samples 
was approved by the FCM/UNICAMP Research Ethics 
Committee (CAAE: 0014.0.144.146–08) and informed 
consent was obtained from parents. The use of the 
xenograft animal model was approved by the CEEA/
UNICAMP Animal Experimentation Ethics Committee 
(Protocol 1766–1).
Synthesis of AS605240. The water-soluble 
potassium salt of AS605240 was synthesized according 
to patent WO 2004007491. Identity and purity were 
confirmed by mass spectrometry and nuclear magnetic 
resonance.
Primary T-ALL cells. Bone marrow mononuclear 
cells were obtained from patients with newly diagnosed 
T-ALL accrued from 2000 to 2013 at Centro Infantil 
Boldrini, Campinas, Brazil. Treatment was performed 
according to the Brazilian GBTLI ALL-99 [41] and 
GBTLI ALL-2009 protocols. NOTCH1, PTEN and IL7R 
were sequenced as described elsewhere [12, 20, 64].
Cell lines culture and survival assays. Cell 
lines were cultured in RPMI-1640 medium, 10% fetal 
bovine serum (FBS), and penicillin/streptomycin at 37°C 
and 5% CO2. Medium was changed 12–24 h before all 
experiments. To measure IC50 values, cells (2–6 × 10
4) 
were incubated for 96 h with increasing concentrations 
of AS605240, prednisolone, L-asparaginase, MTX 
or DNR. To measure Combination Index (CI) values 
between AS605240 and the other drugs, 2-fold ratios of 
the calculated IC50 values (0.25x, 0.5x, 1x, 2x or 4x) of 
each drug were used either in combination or as single 
drugs. Cells were treated for a total of 96 h. When drug 
scheduling was applied, one of the drugs was added 
48 h after the start of the experiment. Cell viability 
was measured by the MTT assay. IC50 and CI values 
were calculated with the GraphPad Prism 5 (GraphPad 
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Software, La Jolla, CA, USA) and Calcusyn (Biosoft, 
Cambridge, UK) [65] softwares, respectively. Calculated 
IC50 values are shown in Supplementary Table 4.
PI3K gene expression signatures. Cell lines (5–
10 × 107) were cultured with the AS605240 IC50 value 
or vehicle for 6 h, RNA was extracted by the phenol-
chloroform method and purified with the RNAeasy Mini 
Kit (Qiagen, Inc., Valencia, CA, USA). Samples were 
processed with the One-Cycle Target Labeling and Control 
Reagents Kit (Affymetrix, Santa Clara, CA, USA) and 
hybridized on HG-U133 Plus 2.0 Arrays (Affymetrix). 
Cryopreserved primary T-ALL cells were thawed, washed 
in RPMI-1640 twice and viable cells were isolated with 
the Dead Cell Removal Kit (Miltenyi, Bergisch Gladbach, 
Germany). Approximately 3 × 106 cells were cultured with 
20 μM of AS605240 or vehicle for 6 h in AIM-V medium 
(Invitrogen, Carlsbad, CA, USA) supplemented with 2 
mM glutamine, 10% FBS, and penicillin/streptomycin at 
37°C and 5% CO2. RNA was extracted with the Illustra 
RNAspin Mini RNA Isolation Kit (GE Healthcare, 
Little Chalfont, UK), processed with the GeneChip WT 
cDNA Synthesis and Amplification Kit (Affymetrix) and 
hybridized on Human Gene 1.0 ST Arrays (Affymetrix). 
Expression values were obtained with the iterPLIER+16 
algorithm and expressed in a log2 scale. Paired Limma 
analysis (http://www.bioconductor.org/packages/2.12/
bioc/html/limma.html) was used to obtain differentially 
expressed genes with FDR adjusted p-value < 0.05 
and Fold-change > 1.5. Cells of each patient or cell 
line treated with AS605240 or vehicle were assigned 
as counterparts for the paired analysis. GSEA analysis 
(http://www.broadinstitute.org/gsea/) [66] was performed 
with 1000 phenotype permutations and default settings. 
Only probesets/transcript clusters annotated with a Gene 
Symbol were used in the analysis. For Connectivity Map 
analysis (http://www.broadinstitute.org/cmap/) [67], only 
probesets identical in HG-U133A and HG-U133 Plus 2.0 
arrays were used. Gene sets were considered significantly 
regulated when p < 0.05 and FDR < 0.25. Ingenuity 
Pathways Analysis (Ingenuity Systems, Redwood City, 
CA, USA) was performed with the Gene Symbols of 
AS605240 responsive genes. Principal Component 
Analysis was performed with the MultiExperiment Viewer 
(http://www.tm4.org/mev.html).
Gene expression of diagnostic T-ALL. Total RNA 
was extracted from T-ALL lysates preserved in guanidine 
isothiocyanate solution using the Illustra RNAspin Mini 
RNA Isolation Kit (GE Healthcare). RNA samples were 
processed with the WT Expression Kit (Ambion, Austin, 
TX, USA) and GeneChip WT Terminal Labeling and 
Controls Kit (Affymetrix), and hybridized on Human 
Gene 1.0 ST Arrays. Expression values were obtained 
with the iterPLIER+16 algorithm and expressed in a log2 
scale. GSEA analysis was performed with 1000 gene set 
permutations. All array files used in this study are publicly 
available through the Gene Expression Omnibus (GEO) 
database under the accession GSE51001. For clinical and 
biological data, refer to Supplementary Table 3.
Quantitative PCR. RNA samples of T-ALL 
primary cells treated with AS605240 or vehicle in 
vitro were submitted to cDNA synthesis with the 
ImProm-II Reverse Transcription System (Promega, 
Madison, USA) and quantitative PCR with HOT 
FIREPol EvaGreen qPCR Mix Plus (Solis BioDyne, 
Tartu, Estonia) in a 7500 Fast Real-Time PCR System 
(Life Technologies, Carlsbad, USA). Expression was 
calculated relative to ABL expression. Primers used 
were: ALOX5AP (forward TAGGAGAGAGAACGCA 
GA, reverse AGGAACAGGAAGAGTATGA), 
BCAT1 (forward AGAAGAAGAACTGGCAAC, 
reverse CACCTTAAATTCACCCCAC), LDHA 
(forward TTCACCCATTAAGCTGTC, reverse 
CAACATTCATTCCACTCC), PRDX4 (forward GTCCAA 
CTGAAATTATCGCT, reverse CCAGGCCAAATGGG 
TAAA) and ABL (forward TGGAGATAACACTCTA 
AGCATAACTAAAGGT, reverse GATGTAGTTGCTTGG 
GACCCA) [68].
Cell signaling assays. PIP3 quantification of 
Jurkat cells (3 × 107) treated for 8 h with AS605240 IC50 
value or vehicle was performed in duplicates using the 
K-2500 PIP3 Mass ELISA Kit (Echelon Biosciences, 
Salt Lake City, UT, USA). Phospho-Akt quantification of 
Jurkat and Molt-4 cells treated for 24 h with increasing 
concentrations of AS605240 or vehicle was performed 
using the Akt [pS473] ELISA Kit (Invitrogen). Western 
blotting analysis of Jurkat cells treated with AS605240 
IC50 values or vehicle was performed using antibodies 
against Akt (#4691, Cell Signaling Technology, Beverly, 
MA, USA), p-Akt (#4060, Cell Signaling Technology), 
Myc (N-262, Santa Cruz Biotechnology, Santa Cruz, CA, 
USA) and β-actin (IM-0075, Rhea Biotech, Campinas, 
Brazil).
Apoptosis analysis. Jurkat cells (1 × 106) treated 
for 8 h with AS605240 IC50 value or vehicle and primary 
T-ALL cells (1.5 × 106) treated for 6 h with 20 μM of 
AS605240 or vehicle were analyzed for apoptosis. Cells 
were either stained with PE Rabbit Anti-Active Caspase-3 
(Becton Dickinson) according to manufacturer's 
instructions, or incubated at 37°C for 15 minutes with 
FITC-conjugated Annexin-V (Invitrogen Corporation) 
and PI 5 μg/mL in Annexin-V binding buffer. Cells were 
analyzed in a FACSCalibur flow cytometer.
Cell cycle and Brdu incorporation assays. For 
cell cycle analysis, Molt-4 cells (2 × 105) were treated 
with the IC50 values of AS605240, MTX and/or vehicle 
for 24 h. Cells were fixed in 70% ethanol, washed with 
PBS and incubated at 37°C for 15 min in 1 mL PI Buffer 
(0.1% Triton X-100, 0.2 mg/mL RNAse, and 20 μg/
mL PI, in PBS). Ten thousand events were collected in 
a FACSCalibur flow cytometer and data was analyzed 
with the ModFit LT 3.3 software (Verity Software House, 
Topsham, ME, USA). For Brdu incorporation assays, 
Oncotarget13115www.impactjournals.com/oncotarget
Molt-4, P12-ICHIKAWA and Jurkat cells (1 × 106) were 
treated for 24 h with AS605240 IC50 values or vehicle, 
pulsed for 30 min with 10 μM BrdU and processed with 
the BrdU Flow Citometry Assay Kit (Becton Dickinson). 
Events (2 × 104) were analyzed in a FACSCanto flow 
cytometer (Becton Dickinson).
In vivo experiments. Primary T-ALL cells were 
thawed, washed with PBS and 1 × 107 cells were injected 
in NOD/SCID (NOD.CB17-Prkdcscid/J) mice (The 
Jackson Laboratory, Bar Harbor, ME, USA) via the tail 
vein. After 10–12 weeks, successfully engrafted mice 
were sacrificed, T-ALL cells were collected from spleen 
and liver and 1 × 107 cells were immediately injected in 
higher number of non-irradiated mice for the following 
experiments. For disease progression experiments, mice 
received 20 mg/Kg of AS605240 (n = 5) or vehicle 
(n = 12), intraperitoneally twice a day, 5 days a week, 
starting on the eleventh day after injection of leukemia cells. 
Number of human CD45+ cells in the peripheral blood 
after red blood cells lysis was regularly measured by flow 
cytometry and exponential growth curves were compared 
with the F test of the best-fit K values. For survival 
analysis experiments, mice were randomly distributed 
into the different treatment groups (5 animals per group) 
when human CD45+ reached ≥ 0.5% of peripheral blood 
cells in half of the animals. Mice were treated with 
30 mg/Kg of AS605240 and/or 5 mg/Kg of dexamethasone, 
intraperitoneally once a day, 5 days a week, for 35 days. 
Kaplan-Meier survival curves were compared using the 
log-rank test with the GraphPad Prism 5 software.
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